Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.30 |
| ▸ | CYP21A2 | P08686 | 2/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100462 | 0.82 | — | — | |
| SCHEMBL16022965 | 0.77 | EPHX2 (0.44) | EPHX2ALDH1A1CYP3A4CYP3A5NAMPT | |
| SCHEMBL5405216 | 0.77 | EPHX2 (0.44) | EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL24735804 | 0.75 | CA1 (0.48) | EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL15893903 | 0.75 | CA1 (0.48) | EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL777414 | 0.75 | CA1 (0.48) | EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL12251504 | 0.73 | POLB (0.41) | EPHX2ALDH1A1NAMPT | |
| SCHEMBL10466187 | 0.73 | GAA (0.40) | ALDH1A1 | |
| SCHEMBL5197 | 0.72 | LMNA (0.42) | ALDH1A1CYP3A4 | |
| SCHEMBL1107023 | 0.71 | CA12 (0.54) | EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232118-A | Protein kinase inhibitory activity small molecule and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-10-25 | — | — | CN | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-8653081-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-02-18 | — | — | US | claimed |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2013-11-07 | — | — | US | claimed |
| US-8410108-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-04-02 | — | — | US | claimed |
| EP-1663994-B1 | TETRAHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | claimed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| JP-4808156-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1912972-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | claimed |
| EP-2091926-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2009-08-26 | — | — | EP | claimed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | claimed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| EP-1912972-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2008-04-23 | — | — | EP | claimed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | claimed |
| EP-1663994-A1 | CONDENSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-25 | — | — | US | claimed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | KCNQ1, KCNN2, KCNH3 | EPHX2 1910/4885ALDH1A1 3086/4885CYP3A4 4208/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | EPHX2 4759/4885ALDH1A1 1685/4885CYP3A4 3971/4885 |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNI3, MYLK2, TNNT2 | EPHX2 3572/4885ALDH1A1 3849/4885CYP3A4 4622/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | EPHX2 3943/4885ALDH1A1 1512/4885CYP3A4 7/4885 |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | EPHX2 3695/4885ALDH1A1 3619/4885CYP3A4 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.